FDA-USPTO Collaboration: Stakeholders Want More Clarity On Orange Book Patent Listings
Executive Summary
Officials from the two agencies note the real-world benefit of cross-training in helping patent examiners find prior art based on product labeling. A USPTO administrative patent judge also nixes a suggestion that the agency hold proceedings to determine if patents were properly listed in the Orange Book.
You may also be interested in...
In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap
Agency sends letters to 10 companies saying they improperly listed patents in US FDA’s Orange Book covering drug-device combination products. FTC does not specify why it believes the patents were improperly listed.
In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap
Agency sends letters to 10 companies saying they improperly listed patents in US FDA’s Orange Book covering drug-device combination products. FTC does not specify why it believes the patents were improperly listed.
FTC Set To Take Enforcement Action Against Drugmakers Over Orange Book Patent Listings
Merger reviews could take into account sponsor's Orange Book behavior. FTC's statement does not detail what would make a patent listing 'improper' but the precedents from court cases against various sponsors should offer industry some guideposts.